baber/WOPTO huggingface dataset:
Patent CA-3069644-A1 (CA)
Inventor: JONGSMA ARNOUD MARC
IPC: H04B13/02
Filed: 2018-07-11
Abstract: An underwater wireless optical communication, UWOC, unit (30) for underwater deployment on a submerged earth layer (12) or structure (14, 16). The UWOC unit is configured for wireless optical communication in an underwater environment, and comprises an optical transmitter (36), an anidolic optical receiver (38), and a processor (44). The optical transmitter is configured to transmit data by emitting an optical signal (80) into the surroundings. The optical receiver includes an optical detector (62), which is omnidirectionally sensitive and configured to receive further optical signals approaching substantially along an azimuthal plane orthogonal to a nominal axis (A) through the UWOC unit. The processor is coupled to the optical receiver, and configured to process received further optical signals. The unit may be configured to determine an inter-unit distance between this unit and a second unit, by sending an optical interrogation signal to the second unit, and receiving an optical response signal from the second unit.
Patent CA-3070493-A1 (CA)
Title: Method for preparing silicon-containing heterocycles
Inventor: DAMKE JAN-ERIK
IPC: C07F7/18
Filed: 2018-02-15
Abstract: The present invention relates to a method for preparing silicon-containing heterocycles of the general formula (I), wherein R1 is hydrogen; R2 and R3 are same or different and are, independently from one another, selected from a linear or branched, substituted or unsubstituted C1-C20 alkyl or C6-C18 aryl residue which may be interrupted by at least one heteroatom; R4 is selected from a linear or branched C1-C20 alkylene residue which may be interrupted by at least one heteroatom; R5 and R6 are same or different and are, independently from one another, selected from the group consisting of hydrogen, a linear or branched, substituted or unsubstituted C1-C20 alkyl or C6- C18 aryl which may be interrupted by at least one heteroatom, and a C4-C8 cycloalkyl, or R5 and R6 may form a ring, preferably a 4- to 8-membered alkyl ring; and n is 0, 1 or 2, preferably 2, said method comprising a one-step reaction of at least one epoxide compound of the general formula (II) and at least one aminoalkoxysilane having a primary amino group in the presence of a catalyst formula (II), wherein R5 and R6 are the same as defined for the general formula (I) above; as well as the use of the silicon-containing heterocycles of the general formula (I).
Patent CA-3070733-A1 (CA)
Title: Appareil pour la quantification radiopharmaceutique d'une partie corporelle
Inventor: HINDORF CECILIA
IPC: A61B6/03
Filed: 2018-07-23
Abstract: L'invention concerne un appareil pour la quantification radiopharmaceutique d'une partie corporelle. L'invention concerne (210) une unité de traitement (30) avec au moins une image gamma d'une partie corporelle. L'au moins une image gamma a été acquise par au moins une caméra gamma configurée pour détecter des rayons gamma et/ou des rayons X. L'au moins une image gamma comprend des données d'énergie spectrale qui comprennent des données qui ont résulté de la dégradation d'au moins un produit radiopharmaceutique. L'unité de traitement est pourvue (220) d'énergies d'émission de photons caractéristiques et de probabilités d'émission associées à la dégradation de l'au moins un produit radiopharmaceutique. L'unité de traitement détermine (230) une activité dudit au moins un produit radiopharmaceutique à une pluralité de positions spatiales dans la partie corporelle. La détermination d'une position spatiale de la pluralité de positions spatiales comprend de générer (240) un spectre synthétique et de corréler le spectre synthétique généré à un spectre expérimental généré à partir des données d'énergie spectrale pour au moins une position dans l'au moins une image gamma qui correspond à cette position spatiale. La génération du spectre synthétique comprend l'utilisation des énergies d'émission de photons et des probabilités d'émission associées à la dégradation de l'au moins un produit radiopharmaceutique. L'unité de traitement détermine (250) une distribution spatiale de l'au moins un produit radiopharmaceutique dans la partie corporelle.
Patent CA-3072674-A1 (CA)
Inventor: LI XIAOJUAN
IPC: H04L47/43
Filed: 2017-08-11
Abstract: Les modes de réalisation de la présente invention concernent un procédé de définition d'un type de PDU, un procédé de définition d'une politique d'UE, et des entités associées. Le procédé de définition d'un type de PDU comprend les étapes suivantes : un UE définit le type de PDU d'une demande de session PDU pendant un processus d'établissement de session PDU, le type de PDU de la demande de session PDU étant défini par l'UE d'après une première condition, la première condition comprenant une version de protocole Internet (IP) correspondant à une application, et l'application étant associée à une session PDU. Selon les modes de réalisation de la présente invention, le type de PDU de la demande de session PDU peut être cohérent avec le type PDU d'une demande d'application, de sorte que l'application peut communiquer normalement.
Patent CA-3073648-A1 (CA)
Inventor: SCHEIDT-PUGA ANA CRISTINA
IPC: A61K38/46
Filed: 2018-08-22
Abstract: The invention provides methods of using a human acid sphingomyelinase (e.g., olipudase alfa) in treating an abnormal bone condition in acid sphingomyelinase deficiency patients such as low bone density, high bone marrow burden, and other skeletal abnormalities presented in acid sphingomyelinase deficiency patients.
Patent CA-3074128-A1 (CA)
Inventor: CAI XIUMEI
IPC: C07K16/18
Filed: 2018-08-28
Abstract: An antibody for being specifically bound to a pro brain-derived neurotrophic factor (pro-BDNF) and a bound epitope. The antibody and the protein are used for treating autoimmune diseases. By inhibiting the activity induced by the pro-BDNF, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephriti, chronic obstructive pulmonary diseases, asthma or cystic fibrosis, multiple sclerosis and other autoimmune diseases are treated.
Patent CA-3075446-A1 (CA)
Inventor: CALLEWAERT NICO
IPC: C12P21/00
Filed: 2018-09-13
Abstract: The present invention provides means and methods for the production in eukaryotic cells of homogeneous forms of small glycan structures which carry terminal galactose residues. In addition, the invention provides glycan-conjugates based on specific coupling with galactose residues present on the recombinant glycoproteins.
Patent CA-3076604-A1 (CA)
Title: Polyacrylate antifoam components for use in fuels
Inventor: BUSH JAMES H
IPC: C10L1/196
Filed: 2018-09-21
Abstract: There is disclosed an antifoam component which includes at least one poly(acrylate) copolymer for use in a fuel. Poly(acrylate) polymers prepared by polymerizing a (meth)acrylate monomer comprising C1 to C30 alkyl esters of (meth)acrylic acid ("multifunctional monomer") are also disclosed. Other poly(acrylate) polymers prepared by polymerizing (i) a (meth)acrylate monomer comprising C1 to C4 alkyl esters of (meth)acrylic acid ("solubility monomer"); (ii) a (meth)acrylate monomer comprising C5 to C12 alkyl esters of (meth)acrylic acid ("surface tension monomer"); and (iii) optionally at least one additional monomer comprising a solubility monomer, a surface tension monomer, a monomer comprising C1 to C30 alkyl esters of (meth)acrylic acid ("multifunctional monomer"), or combinations thereof are also disclosed.
Patent CA-3077466-A1 (CA)
Title: Sports glove having improved wrist strap and dorsal splint system
Inventor: CLEMENT KEN
IPC: A63B71/14
Filed: 2016-04-29
Abstract: A protective sports glove worn by athletes during training or for use in a combative event to protect against injury and increase performance (including but not limited to total force generation, grip strength, striking force and speed, muscular endurance, time to contraction, etc.). These gloves are engineered with a dorsal splint system and a cooperating adjustable dual strapping wrist tie system to secure the gloves to the contour of the hands, to ensure they remain tight and fixed, and to support the wrist from excessive bending. The dual strapping system with the dorsal splint system provides increased wrist/hand rigidity mirroring a tightness of hand wrap bandages for maximal bone and tendon support of the hands and wrists, and this novel tie system increases the transfer of force generation to the point of impact.
Patent CA-3079115-A1 (CA)
Title: Testing device
Inventor: JUNES AKI
IPC: G01R31/28
Filed: 2020-04-20
Abstract: The present invention provides a testing device (100) for electrically testing integrated circuits on a wafer (102). The testing device (100) comprises a vacuum chamber (109), a chuck (101) for holding the wafer (102), a probe card (103) for electrically contacting the integrated circuits, and a radiation shield (107) arranged inside the vacuum chamber (109) and enclosing the chuck (101) and the probe card (103). In the testing device (100), the vacuum chamber (109) is provided with a gate valve (123), the radiation shield (107) is provided with a hatch (122), and the testing device (100) comprises a wafer loading assembly (125) for loading the wafer (102) onto the chuck (101) through the gate valve (123) and the hatch (122).
Patent CA-3079620-A1 (CA)
Inventor: NIKOLAKAKIS IOANNIS
IPC: A61K31/519
Filed: 2018-10-05
Abstract: Pellets comprising these Self-Emulsifying Drug Delivery Systems SEDDS of poorly water soluble weakly ionizable or non-ionizable active pharmaceutical ingredients and oral pharmaceutical dosage forms thereof. The pellets comprise a mixture of microcrystalline cellulose and colloidal silicon dioxide, and are produced by extrusion/spheronization. The active pharmaceutical ingredient is incorporated in SEDDS comprising a mixture of a medium chain triglyceride and a non-ionic surfactant.
Patent CA-3080780-A1 (CA)
Title: System and method for purging a fuel manifold of a gas turbine engine using a pump
Inventor: SHENOUDA ANTWAN
IPC: F23R3/28
Filed: 2020-05-13
Abstract: Methods and systems of operating a gas turbine engine in a low-power condition are provided. In one embodiment, the method includes supplying fuel to a combustor by supplying fuel to a first fuel manifolds and a second fuel manifold of the gas turbine engine. The method also includes, while supplying fuel to the combustor by supplying fuel to the first fuel manifold: stopping supplying fuel to the second fuel manifold; and using a pump to drive gas into the second fuel manifold to flush fuel in the second fuel manifold into the combustor and hinder coking in the second fuel manifold and associated fuel nozzles.
Patent CA-3083813-A1 (CA)
Title: Stratifie a structure synchrone
Inventor: DOEHRING RAINER
IPC: B44C1/24
Filed: 2017-12-29
Abstract: La présente invention concerne un procédé pour la fabrication d'un stratifié, en particulier un stratifié pressé en continu, CPL, qui peut être utilisé, par exemple, comme stratifié de surface dans la fabrication de plans de travail ou de panneaux de plancher. Le procédé comprend la fourniture d'une feuille de finition et d'une structure de support, ainsi que le pressage de la feuille de finition avec la structure de support dans un procédé CPL.
Patent CA-3085933-A1 (CA)
Inventor: MITCHELL AOY TOMITA
IPC: C12P19/34
Filed: 2018-12-14
Abstract: La présente invention concerne des procédés et des compositions d'évaluation de la compatibilité d'une greffe pour la transplantation ou l'implantation en mesurant les acides nucléiques totaux et/ou spécifiques sans cellules (tels que l'ADNac) et/ou la lyse cellulaire. Plus particulièrement, le procédé comprend l'obtention d'une quantité d'ADNac total et/ou d'ADNac spécifique d'une greffe libérée à partir d'une greffe potentielle (par exemple, ex vivo), par exemple, avant la mise en contact de la greffe potentielle avec les cellules sanguines d'un bénéficiaire potentiel, et/ou suite à la mise en contact de la greffe potentielle ou de ses cellules avec des cellules sanguines provenant d'un bénéficiaire potentiel, l'évaluation de la(des) quantité(s) pour déterminer la compatibilité de la greffe potentielle pour la transplantation ou l'implantation.
Patent CA-3086023-A1 (CA)
Inventor: Zhang Keya
IPC: A21D13/02
Filed: 2018-12-17
Abstract: A phospholipase A1 characterized by having an sn1/sn2 specificity ratio of about 5/45 or greater wherein said phospholipase A1 has a lysophospholipase/phospholipase activity ratio of less than 0.02 is presented in conjunction with methods for use in lipid containing food matrix, baking and making dough with the phospholipase and also including baking improvers using the disclosed phospholipase A1.
Patent CA-3087608-A1 (CA)
Inventor: DERKS RENE
IPC: B65B25/06
Filed: 2020-07-17
Abstract: The invention relates to a packaging tray (1), produced from a thermoformed plastics sheet, with a base (10), sidewalls (11, 12) and a sealing edge (13) which is formed peripherally on the upper side of the sidewalls (11, 12) and onto which a sealing film (2) can be placed and can be bonded to the sealing edge (13), in which the sealing edge (13) is formed with a contact surface, which is provided for supporting the sealing film, with a profiling in the form of projections (133) in each case forming part of the contact surface and with depressions (134) which run between adjacent projections (133) and interrupt the contact surface, wherein the depressions (134) in each case define a receiving volume.
Patent CA-3090913-A1 (CA)
Title: Benzodiazepine derivative hydrochloride and crystal form, preparation method, and application thereof
Inventor: LI QINGENG
IPC: A61K31/5517
Filed: 2019-02-13
Abstract: The present invention provides a crystalline form of a benzodiazepine derivative hydrochloride of Formula I or its ethanolate, wherein R is methyl or ethyl. The present invention also provides a method of preparing the crystal fomi of the compound of Formula I and a pharmaceutical composition comprising the crystal form. The present invention further provides uses of the crystalline form of the compound of Formula I, for example, as intravenous anesthetics.
Patent CA-3091459-A1 (CA)
Inventor: MICHISHITA HARUYASU
IPC: C21B13/00
Filed: 2019-03-25
Abstract: An oxygen injection system for a direct reduction process, including: a common circumferential gas injection header adapted to be coupled to an oxygen source and an enrichment natural gas source and adapted to deliver oxygen from the oxygen source and enrichment natural gas from the enrichment natural gas source to a reducing gas stream flowing through a conduit axially disposed within the common circumferential gas injection header through a plurality of circumferentially disposed ports to form a bustle gas stream; wherein the common circumferential gas injection header includes a circumferential oxygen injection header adapted to deliver the oxygen from the oxygen source to the reducing gas stream through the plurality of circumferentially disposed ports and a circumferential enrichment natural gas injection header adapted to deliver the enrichment natural gas from the enrichment natural gas source to the reducing gas stream through the plurality of circumferentially disposed ports.
Patent CA-3091635-A1 (CA)
Inventor: RANKIN DAVID BENJAMIN
IPC: G09B19/00
Filed: 2019-02-15
Abstract: Embodiments provided herein measure metrics of an athletic action and an object associated therewith, and more particularly, to measuring the metrics and characteristics of a baseball during the wind-up, release, flight, and catch of a pitch sequence. Methods may include: receiving, from at least one motion sensor associated with an object, acceleration data and angular velocity data of the object in response to an athletic action performed on the object; processing the acceleration data to establish vector rotation data between a frame of reference of the object and an Earth frame of reference; applying the vector rotation data to the acceleration data to obtain acceleration of the object in the Earth frame of reference; applying the vector rotation data to the angular velocity data to obtain angular velocity of the object in the Earth frame of reference.
Patent CA-3094988-A1 (CA)
Title: Composes de thienopyrimidinone
Inventor: W H CHAN KYLE
IPC: C07D495/04
Filed: 2019-03-28
Abstract: La présente invention concerne des composés qui modulent la fonction des protéines et/ou rétablissent l'homéostasie des protéines. L'invention concerne des procédés de modulation de maladies, de troubles, d'états ou de réponses à médiation par des protéines. L'invention concerne également des compositions, y compris en combinaison avec d'autres agents thérapeutiques.
Patent CA-3096641-A1 (CA)
Inventor: WUST EDGAR
IPC: A61L27/50
Filed: 2020-10-20
Abstract: ABSTRACT  The invention relates to a seal for sealing a bone canal opening during the application of bone cement into the cancellous bone of a bone canal. The invention also relates to a device for applying bone cement into the cancellous bone of a bone canal comprising the seal according to the invention, and a method for applying bone cement by means of the device according to the invention.
Patent CA-3097488-A1 (CA)
Title: Monolithic phosphor composite for sensing systems
Inventor: JOHNSON NOAH JOE
IPC: C09K11/84
Filed: 2020-10-29
Abstract: Examples of a monolithic phosphor composite for measuring a parameter of an object are disclosed. The composite comprises a thermographic phosphor and a metal oxide material that are dried and calcinated at high temperatures to form a ceramic metal oxide phosphor composite. The ceramic metal oxide phosphor composite is used in an optical device for measuring the parameter of the measuring object. The device comprises a fiber optic probe with a light guide, a light source operatively coupled to the fiber optic probe to provide excitation light into the light guide, a monolithic ceramic metal oxide phosphor composite functionally coupled to a tip of the fiber optic probe, a sensor operatively coupled to the fiber optic probe to detect the emitted light and a processing unit functionally coupled to the sensor to process the emitted light. When the monolithic ceramic metal oxide phosphor composite is illuminated with the excitation light it emits light in a wavelength different from the excitation light and a change in emission intensity at a single wavelength or the change in intensity ratio of two or more wavelengths, a shift in emission wavelength peak or a decay time of the phosphor luminescence is a function of the measuring parameter.
Patent CA-3098564-A1 (CA)
Title: Method for preparing alkynyl pyridine prolyl hydroxylase inhibitor
Inventor: LU GANG
IPC: A61K31/44
Filed: 2019-05-23
Abstract: Provided is a method for preparing an alkynyl pyridine prolyl hydroxylase inhibitor. In particular, the method involved uses 3-substituted-5-bromopyridine-2-carboxylic acid protected by different protection groups as raw materials, and by means of condensation, Sonogashira coupling and deprotection, the target compound is obtained. The process reaction conditions are simple, and have no harsh reaction conditions, strong operability, and stable amplification.
Patent CA-3101323-A1 (CA)
Title: Dosing regimen for the treatment of pi3k related disorders
Inventor: YELESWARAM KRISHNASWAMY
IPC: A61P35/00
Filed: 2019-05-30
Abstract: The present application provides methods of treating PI3Kd related disorders using pyrazolopyrimidine derivatives.
Patent CA-3101810-A1 (CA)
Title: Method for enhancing embryo implantation
Inventor: TREMELLEN KELTON PAUL
IPC: A61P15/08
Filed: 2019-05-29
Abstract: A method of enhancing embryo implantation in a subject is disclosed which comprises administering to the uterine cavity of the subject a formulation comprising copper and/or zinc in an amount effective to stimulate endometrial production of leukaemia inhibitory factor (LTF) and' or vascular endothelial growth factor ( VEGF). Alternatively, a device may be inserted into the uterine cavity of the subject, wherein the device comprises copper and/or zinc, for a period of time that is effective to stimulate endometrial production of LIF and/or VEGF. The method is suitable for use with women undergoing treatment by any of the assisted reproductive technologies, such as those involving the transfer of embryos such as in vitro fertilisation (IVF) and variants including IVF-ICSI (intracytoplasmic spenn injection) and m vitro maturation (1VM) treatments, as well as intrauterine-insemination (IUI) therapy. However, the method is also applicable for women wanting to improve their prospects of pregnancy through natural conception.
Patent CA-3104413-A1 (CA)
Inventor: THOMPSON MICHAEL
IPC: G10L25/51
Filed: 2019-06-18
Abstract: A method of recorded message detection from answering machine is provided. In this an audio stream is received and a set of landmark features is identified in a section of the audio stream. From these landmark features an audio finger print for the section of the audio stream is determined. This audio finger print is compared with at least one of the plurality of stored audio finger prints, each derived from a respective audio stream. It is determined that the received audio stream is the recorded message of an answering machine if a derived audio finger print is substantially equivalent to one of the plurality of stored audio finger prints representing a recorded message. The landmarks are derived by identifying points of inflection in the audio stream comprising stepping through sample values and comparing the amplitude of immediately adjacent sample values to the point of inflection. If the difference in amplitude exceeds a threshold the point of inflection is confirmed as a landmark.
Patent CA-3104659-A1 (CA)
Title: Method
Inventor: VOUGIOUKALAKIS GEORGIOS C
IPC: A61P35/00
Filed: 2018-06-21
Abstract: The invention provides mitochondria-targeted chemiluminescent agents and their use in methods of photodynamic therapy (PDT). In particular, the invention provides compounds of general formula (I), and their pharmaceutically acceptable salts: (I) in which A represents a chemiluminescent moiety; each L, which may be the same or different, is either a direct bond or a linker; each B, which may be the same or different, represents a mitotropic moiety; n is an integer from 1 to 3, preferably 1; and x is an integer from 1 to 3, preferably 1. Such compounds find particular use in the treatment of deeply- sited tumours, e.g. glioblastoma multiforme (GBM), when used in combination with a photosensitizer or photosensitizer precursor.
Patent CA-3107455-A1 (CA)
Inventor: MYNENI SIRISHA
IPC: H04L45/42
Filed: 2019-08-14
Abstract: Some embodiments provide a simplified mechanism to deploy and control a multi- segmented application by using application-based manifests that express how application segments of the multi-segment application are to be defined or modified, and how the communication profiles between these segments. In some embodiments, these manifests are application specific. Also, in some embodiments, deployment managers in a software defined datacenter (SDDC) provide these manifests as templates to administrators, who can use these templates to express their intent when they are deploying multi-segment applications in the datacenter. Application-based manifests can also be used to control previously deployed multi- segmented applications in the SDDC. Using such manifests would enable the administrators to be able to manage fine grained micro-segmentation rules based on endpoint and network attributes.
Patent CA-3107781-A1 (CA)
Title: A health promoting device
Inventor: STROM VIKTOR
IPC: A61F7/02
Filed: 2018-08-01
Abstract: There is provided a health promoting device (10) which consists of a bag (11) having a sealed cavity (13) which is at least partly filled with soapstone powder. The bag may be made of an elastomer material.